is a rare genetic disorder that is characterized by episodes of unpredictable painful swelling. To better understand the challenges of Canadians living with HAE our objective was to gather real world attack profile data. METHODS: In 2017-2018, the first National Canadian HAE survey was electronically sent to all HAE Canada members. The following data was based solely on adult participants. RESULTS: Among 104 participants with HAE they reported a diagnosis of: Type 1 or 2 C1-inhibitor protein deficiency (60%), HAE with normal C1-inhibitor (26%), acquired angioedema (4%), and unsure of diagnosis (10%). In the last year, 78% were symptomatic, 11% were asymptomatic, and 11% were unsure. Regarding their frequency of attacks: 61% had 7 or more attacks, 22% had 1-6 attacks, 6% had no attacks, and 10% were unsure. Identifiable attack triggers vary from stress (87%), typing/writing (78%), trauma (70%), illness (61%), medical procedures (61%), anxiety (55%), and Ace Inhibitors (6%). Other factors that increase HAE symptoms include: menopause (9%), estrogen contraceptives (33%), and menstruation (47%). To treat these attacks, 84% use an agent, compared to 16% who do not. CONCLUSIONS: Our findings demonstrate the majority of participants are knowledgeable in identifying their triggers and managing their attacks. Results show improvements are necessary for proper diagnosis and awareness of the disease. Since the number of people living with HAE is estimated, our data is limited to the respondents and may not represent the broader Canadian HAE population.
